For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Sequestome-1 or ubiquitin binding protein p62 (SQSTM1 p62) is an autophagosome cargo protein that targets other proteins that bind to it for selective autophagy. SQSTM1 p62 is an adaptor protein which is initially phosphorylated by ULK1 on Serine 407, then on Serine 403 by casein kinase 2 or TBK1. The phosphorylation on Ser403 increases its affinity for ubiquitin chains, thus enabling SQSTM1 p62 to bind to ubiquitinated cargo proteins. Ubiquitinated proteins or ubiquitin coated mitochondria associated with SQSTM1 p62 proteins are taken away in phagosomes, whose content is cleared out after lysosomal fusion. SQSTM1 p62 is implicated in Alzheimer’s disease, Huntington’s disease, NASH, and numerous types of cancer.
The AlphaLISA SureFire Ultra Human and Mouse Total SQSTM1 p62 Detection Kit is a sandwich immunoassay for the quantitative detection of total SQSTM1 p62 in cellular lysates, using Alpha Technology.
檢測點(200-50,000) | 500 Assay Points |
---|---|
檢測目標 | SQSTM1 p62 |
檢測技術 | Alpha |
自動化兼容 | Yes |
檢測方法 | Alpha |
實驗類型 | In vitro |
產品品牌名稱 | AlphaLISA SureFire Ultra |
運輸條件 | 藍冰 |
Target Species | Human, Mouse |
治療領域 | Neuroscience, Oncology |
產品尺寸 | 500 Assay Points |
Find out about our range of integrated solutions for drug discovery screening in this e-brochure.
Our screening solutions for high-throughput screening, phenotypic screening and data analysis help to streamline drug discovery workflows in labs across the globe. Our portfolio includes automat ...
Product brochure for the Alpha Technology, a versatile, no wash, homogeneous assay technology that's suitable for a broad range of applications.
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater ...